Abstract:Clinical efficacy of EGFR inhibitors (EGFRi) in glioblastoma patients has been limited by a multitude of resistance mechanisms. We hypothesized that these mechanisms emerge upstream of the interface between EGFR signaling and fundamental cellular processes, such as DNA damage response (DDR), without altering this interface. Thus, synthetic lethal interactions targeting this interface should persist despite acquired resistance to EGFRi. To test this hypothesis, we performed an RNAi screen to identify DDR genes required for viability in glioblastoma cells dependent on EGFR signaling (through expression of the oncogenic EGFRvIII) and identified polo-like kinase 1 (PLK1). In synchronous and asynchronous populations, EGFRvIII expressing glioblastomas harbored increased levels of the p-Thr210 PLK1 (an activated form of PLK1). Moreover, EGFRvIII expression was associated with elevated PLK1 expression in the TCGA glioblastoma dataset (p = 0.044). PLK1 Inhibition (by BI2536) induced an increase in the proportion of cells that co-stained for p-Histone H3 and γH2AX foci, suggesting accumulation of mitotic DNA damage. This effect was exacerbated by EGFRvIII expression, implicating induction of mitotic DNA damage as a major contributor to the observed synthetic lethality. Using time-lapsed imaging, we showed that EGFRvIII expression induced the formation of aberrant mitosis as well as prolonged mitotic progression. Further supporting an essential role for PLK1 in suppressing DNA damage accumulation, BI2536 treatment significantly enhanced the in vitro and in vivo tumoricidal effects of the DNA damaging chemotherapy, temozolomide. Moreover, PLK1 inhibition suppressed the accumulation of pS14 Rad51 (an active form of Rad51 that is required for homologous recombination (HR)) as well as overall HR efficiency in the DR-GFP assay. The tumoricidal and TMZ effects of PLK1 inhibition were observed across a panel of eight independent EGFRvIII glioblastoma clones that had acquired distinct resistance mechanisms to EGFRi. These results suggest therapeutic opportunities in targeting the interface between oncogenic signaling and DDR.

Dual PLK1 and STAT3 Inhibition Promotes Glioblastoma Cells Apoptosis Through MYC

Inhibition of Mesenchymal Phenotypes in Glioblastoma by Combined Targeting of NF-κB and STAT3 Pathways

STEM-43. GSK3β PROMOTES THE BMX-MEDIATED STAT3 ACTIVATION TO MAINTAIN GLIOBLASTOMA STEM CELLS

PLK1 Inhibition Promotes Apoptosis and DNA Damage in Glioma Stem Cells by Regulating the Nuclear Translocation of YBX1

RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation

Correction To: Synergism Between the Phosphatidylinositol 3-Kinase P110β Isoform Inhibitor AZD6482 and the Mixed Lineage Kinase 3 Inhibitor URMC-099 on the Blockade of Glioblastoma Cell Motility and Focal Adhesion Formation

Pyrimidine Compounds By4003 and By4008 Inhibit Glioblastoma Cells Growth Via Modulating Stat3 Signaling Pathway

EZH2-STAT3 signaling pathway regulates GSDMD-mediated pyroptosis in glioblastoma

Antitumor Activity Of Novel Pyrazole-Based Small Molecular Inhibitors Of The Stat3 Pathway In Patient Derived High Grade Glioma Cells

Myb Repression Mediates Stat5b-knockdown-induced Apoptosis and Inhibits Proliferation of Glioblastoma Stem Cells

Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway

Synthetic Lethality Through GSK3 Inhibition in Glioma Stem Cells Via the WNT-WWC1-YAP Axis

Dual Inhibition of Src and PLK1 Regulate Stemness and Induce Apoptosis Through Notch1-SOX2 Signaling in EGFRvIII Positive Glioma Stem Cells (Gscs).

Abstract 1720: MSK1 Mediates PI3K Inhibition Resistance by Induction of Β-Catenin Phosphorylation in Glioblastoma

DN-01 * BYPASSING GLIOBLASTOMA RESISTANCE TO EGFR INHIBITORS BY SYNTHETIC LETHALITY

PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition

GSK3 Palmitoylation Mediated by ZDHHC4 Promotes Tumorigenicity of Glioblastoma Stem Cells in Temozolomide-Resistant Glioblastoma Through the EZH2-STAT3 Axis

A Noval STAT3 Pathway Inhibitor Suppresses the Self-renewal and Induces Apoptosis in Glioblastoma Stem Cells

Sensitization Of Glioma Cells To Tamoxifen-Induced Apoptosis By Pl3-Kinase Inhibitor Through The Gsk-3 Beta/Beta-Catenin Signaling Pathway